About This EventTRex Bio, Inc. (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue regulatory T cell (Treg) biology for the discovery and development of immunoregulatory medicines, visits the Nasdaq MarketSite in Times Square. TRex Bio, Inc. is developing medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases.
Detailed price information for Timken Company (TKR-N) from The Globe and Mail including charting and trades.
Trex Co Inc (TREX) posts 26% sales growth to a record $360 million, lifts full-year guidance, and eyes margin expansion as the Little Rock facility ramps toward 2027.
Tipranks Press Release.
Detailed price information for Conocophillips (COP-N) from The Globe and Mail including charting and trades.
TRex Bio has filed a preliminary prospectus for an initial public offering of about 8.3 million comm
Trex Co (NYSE:TREX) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
TRex Bio (TRXB) IPO: Phase 1b atopic dermatitis lead, Eli Lilly collaboration, and a growing autoimmune pipeline. Read the full analysis here.
Detailed price information for Vertiv Holdings (VRT-N) from The Globe and Mail including charting and trades.
Tipranks Press Release.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at home construction materials stocks, starting with Trex (NYSE:TREX).
Trex and Worthington have been highlighted in this Industry Outlook article.
This is the newest page. Registered accounts read further back.